Objective: To systematically review published clinical trials of the pharmacotherapy of Alzheimer disease (AD).
A lzheimer disease is the most common neurodegenerative disorder diagnosed in older individuals worldwide, and Canada is no exception. In 2007, there will be an estimated 97 000 new cases of dementia. 1 This will rise to 111 560 new cases yearly in 2011. 1 By 2031, more than 750 000 Canadians will have some form of dementia. Of these new cases, about 509 000 will suffer from AD. 2 Currently, an estimated 290 000 Canadians aged 65 years and older have AD, 2 and almost 25% of Canadians have someone with AD in their family. In the 100 years since Alois Alzheimer documented the disease, much progress has been made in its understanding and treatment. In particular, the past 25 years have seen significant advances in the pharmacotherapy AD. This review summarizes some of the current evidence for symptomatic drug treatments, the design of ongoing studies attempting to modify disease progression, and the challenges facing AD pharmacotherapy. Neuropsychiatric issues and management are discussed in a companion article. 3 This discussion uses a stage-specific approach that examines presymptomatic impairment, MCI, and mild, moderate, and severe stages of dementia.
Presymptomatic AD
Currently, there is no established pharmacotherapy to treat presymptomatic stages of AD. However, as we continue to elucidate the pathophysiology and molecular biology of AD, we may in the future be able to provide therapy with earlier detection (for example, with biomarkers) and risk stratification.
Mild Cognitive Impairment
The concept of MCI was operationalized by Peterson et al in 1999. 4 Over the years, it has become clear that MCI encompasses a heterogeneous group with varying etiologies and prognoses. Currently, MCI as a syndrome can be clinically classified as shown in Table 1 . Amnestic MCI is a subgroup of MCI comprising individuals who present with memory complaints and measurable decline on objective testing ( Table 2 ). Earlier data show that individuals with amnestic MCI progress to AD at a rate of 10% to 15% yearly, compared with healthy control subjects, who convert at a rate of 1% to 2% yearly. 4, 56 The Memory Impairment Study (n = 769), a 3-year, multicentre, randomized trial of subjects with amnestic MCI evaluated at specialized memory clinics across North America, demonstrated conversion rates to AD of 16% yearly, 6 while another study (n = 161) using similar criteria in a population sample demonstrated conversion rates of 64% after 2 years. 7 A recent study looking at conversion rates over 10 years demonstrated that 44% of individuals with amnestic MCI (n = 64) developed AD over that period. 8 This study also showed that the annual conversion rate was highest during the initial phase and decreased over longer follow-up intervals. While we await further results of ongoing longitudinal population and clinical studies to more accurately determine the rate of progression and the prognosis for amnestic MCI, it is evident that these individuals are neither normal nor demented and that they represent an important target group for pharmacologic as well as nonpharmacologic interventions.
Although there are currently no approved therapies for the symptomatic treatment of amnestic MCI, we will discuss clinical trials conducted thus far as well as emerging therapies.
Cholinesterase Inhibitors
According to the findings of a central cholinergic deficit in individuals with amnestic MCI, 9 treatment with ChEIs could theoretically have beneficial effects. However, RCTs of MCI treatment with ChEIs that ranged from 6 months to 3 years have so far been largely unsuccessful. A 6-month study with donepezil showed no differences in the primary outcome measures of cognition and clinician-rated global change, compared with placebo, 10 although benefits were observed in secondary measures of the ADAS-cog, 11 Digit Span Backwards, and Symbol Digit Modalities tests. The Memory Impairment Study, 6 conducted over a period of 3 years, showed no differences in the probability of progression from amnestic MCI to AD in patients randomized to donepezil or vitamin E, compared with placebo. 6 However, the donepezil group did demonstrate significant differences in various measures, with a delay in progression to AD during the first year. ApoE4 carriers also demonstrated prolonged response to donepezil over 24 months. 6 Potential reasons for the apparent lack of sustained benefit include compensatory upregulation of central cholinergic activity, lack of sensitivity in the cognitive outcomes (ceiling effects), and heterogeneity among patients. 12 If there is benefit, it seems limited and transient. 13 Similar trials with rivastigmine 14 and galantamine 15 did not demonstrate significant differences in time to conversion to AD, although galantamine treatment was associated with a reduced rate of whole-brain atrophy. Overall, there is insufficient evidence at this time to recommend ChEIs for use in individuals with MCI. However, donepezil has demonstrated promise for delaying progression from MCI to AD; in future, it is possible that early initiation in individuals at high risk of progression to AD (for example, those who are ApoE4 positive) may be advised if subsequent evaluation(s) show benefit. 16
Ginkgo Biloba
Biologically, Ginkgo biloba acts mainly as an antioxidant. In addition, it has been suggested that it increases tolerance to hypoxia and improves blood rheology and vasoregulating capacity, with improved blood flow; prevents posttraumatic or toxin-induced brain edema; and inhibits platelet factors, potentially leading to a neuroprotective action. 17 There have been no published data on the effects of Ginkgo biloba on individuals with MCI. A previous study in subjects with age-associated memory impairment compared Ginkgo biloba with placebo and showed no treatment benefit at the end of 6 months. 17 Two studies 18, 19 using Ginkgo biloba are ongoing; of 5 and 7 years' duration, respectively, their primary end points are reduction of the incidence of dementia in elderly subjects with no memory complaints or with some complaints but without measurable decline.
AMPAkines
AMPAkines are a new class of drugs that have been demonstrated to modify and enhance cognition through their actions on glutamate as an excitatory neurotransmitter. Rapid transmission is mediated via ionotropic glutamate receptors such as the AMPA, kainate, and NMDA receptors. Drugs acting on the AMPA (known as AMPAkines) and NMDA receptors have been shown to enhance cognition and memory by mechanisms of long-term potentiation and release of brain-derived neurotrophic factor. 20, 21 Treatment of MCI with AMPAkines is in Phase II trials. 22
Vitamin E
The Memory Impairment Study showed no benefit of high-dose vitamin E (2000 IU daily) in regard to progression to AD at the end of 3 years. 6 increased cardiovascular mortality with high-dose vitamin E has also dampened enthusiasm for its use. 23 There is currently no evidence that vitamin E is effective in slowing the progression of MCI to dementia.
Antiamyloid Therapies
The production and accumulation of Ab peptide is considered by many to be the key factor in the pathogenesis of AD. Antiamyloid therapies, if successful in treating mild AD, have the potential to delay the onset of AD in individuals at higher risk, such as those with MCI. We discuss specific amyloid-acting drugs below in the section on Disease-Modifying Treatments for AD.
Alzheimer Disease
The current definition of AD requires a clinically diagnosed dementia, that is, decline in 2 cognitive domains causing impairment in social and occupational functioning. The 2 classes of drugs approved for the treatment of AD in Canada are the ChEIs (for mild-to-moderate AD) and the NMDA receptor antagonist memantine (for moderate-to-severe AD).
Cholinesterase Inhibitors
Donepezil, rivastigmine, and galantamine are now therapeutic mainstays in the treatment of mild-to-moderate AD, with Level 1a evidence of efficacy. Their symptomatic benefits were initially demonstrated over 6 months, with the ADAS-cog and the CIBIC+ measures as primary end points, 11, 24 and measures of ADL, behavioural and mood changes, and caregiver burden as secondary end points. [25] [26] [27] Other symptomatic benefits observed in clinical practice include improved attention, initiative, social interactions, and involvement in domestic activities. 28 Subsequently, 2 prospective RCTs using donepezil for 12 months showed benefit in reducing the risk of functional decline 29 and maintaining the MMSE 30 at baseline, compared with placebo. 31 Long-term, open-label extension trials (specifically, galantamine for 36 months, donepezil for 24.5 months, and rivastigmine for 26 months) suggest a sustained cognitive benefit on the basis of ADAS-cog scores. [32] [33] [34] Analyses of data collected over 5 years suggest benefits over a range of domains, including cognition, providing rationale for long-term treatment with a ChEI. 35 However, it is important to bear in mind that studies with open-label extensions have several biases, including selective dropout and survivor effects, and the results may not be generalizable to patients at large.
A metaanalysis of RCTs of all 3 ChEIs (with durations of 3 to 6 months) showed that the NNT for cognitive response measured on the ADAS-cog was 10 (95%CI, 8 to 15) and that the NNT for global response measured on the CGI-Change 24 or CIBIC+ was 12 (95%CI, 9 to 16). 36 The NNH one additional patient from adverse events was 12 (95%CI, 10 to 18). A systematic review published in early 2006 also concluded that use of ChEIs resulted in statistically significant improvement of ADAS-cog scores, compared with placebo; however, the improvements in QOL measures were mixed, and the impact on QOL could not be assessed with certainty. 37 This review concluded that ChEIs could delay cognitive impairment in mildly to moderately severe AD for at least 6 months and mentioned the limited ability of outcome measures to detect clinically significant change in treated patients. In terms of efficacy, a 2006 Cochrane review stated that, despite the slight variations in modes of action, there was no evidence of any differences among the 3 drugs. 38 The efficacy of ChEIs in treatment of severe dementia has recently been studied in a 6-month, double-blind, parallel-group, placebo-controlled randomized study 39 that used donepezil and involved 248 patients 40 living in 50 Swedish assisted-care facilities and suffering from severe AD (defined as MMSE scores of 1 to 10 and Functional Assessment Staging 40 of 5 to 7c). Donepezil or placebo were increased from 5 to 10 mg at 1 month and the dosage was adjusted according to tolerability. In the primary analysis at 6 months, patients on donepezil differed from those receiving placebo by 5.7 points on the SIB 41, 42 (P = 0.008), 1.7 points on the ADCS-ADL sev 43, 44 (P = 0.03), and 1.4 points on the MMSE (P = 0.009). The differences were not significant for the NPI 45 and the CGI-Improvement 46 scales. Tolerability was good, except for diarrhea and hallucinations, which were reported at more than twice the rate in donepezil-treated patients, compared with those on placebo. This study was pivotal in getting from the US FDA and Health Canada an extension of the donepezil label to severe stages of AD. A multinational study comparing donepezil to placebo in severely ill patients still in the community showed similar findings. 47 In another study 48 involving a population of patients with moderate-to-severe AD (defined as an MMSE score of 5 to 12) but still living in the community, similar dosages of donepezil showed large effects on the SIB (7.42, P = 0.0017) and the MMSE (1.99, P = 0.0022) after 6 months, compared with placebo; equivalent measures of ADL, global change, and the NPI were significantly different. It is thus clear that there may be measurable benefits in treating patients suffering from moderate-to-severe AD with donepezil if they have never had a therapeutic trial with a ChEI. The question is whether at that stage of disease these benefits are clinically relevant. 49 Newer strategies to evaluate the effects of treatment for severe dementia include recent development of a new instrument (the SWE Tool) 50, 51 in Sweden. This instrument covers 5 domains with 20 items that are more sensitive to changes in severe dementia and will provide a more useful assessment of treatment response in this group of patients.
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The GAS 52, 53 may also prove useful if adapted to the more severe stages of AD.
Memantine
There is Level 1a evidence for the use of Memantine (an uncompetitive, moderate-affinity, voltage-dependent NMDA antagonist) in moderate-to-severe AD. The first study was a 12-week trial 54 (n = 166) comparing 10 mg daily of memantine with placebo in subjects from nursing homes, 51% of whom had vascular dementia. These subjects showed significant global improvement on the CGI-Change but no significant difference in the Behaviour Rating Scale for Geriatric Patients, 55 compared with placebo. More evidence came from 2 subsequent trials of 24 to 28 weeks' duration. The Reisberg trial (n = 252) 56 compared memantine monotherapy with placebo, and the Tariot trial (n = 404) 57 evaluated combination therapy with memantine or placebo added on to a stable dosage of donepezil. There were significant differences in favour of memantine on the CIBIC+, ADCS-ADL, 
Agent

Level of evidence Remarks
Antioxidants There is evidence for a delay in progression of AD with high-dose vitamin E alone but not when combined with selegiline. 88 Toxicity above 400 iu daily demonstrated by metaanalysis. 22 A large prevention trial testing vitamin E (as well as selenium) over 12 years has been completed, and results are pending. 89 B 12 and folate Currently, there is no evidence to suggest that vitamin B 12 and folate are effective in the routine treatment of AD, 90 but ongoing trials may provide evidence in primary prevention.
Evidence of the effects of 3 to 7 years' treatment with B vitamins on cognitive function will be eventually available from a metaanalysis of 12 large homocysteine-lowering trials for prevention of cardiovascular events. 91 Estrogens There is conflicting evidence over the use of estrogens in dementia, with Level 2a evidence of a protective effect and Level 1b evidence of a harmful effect. 92, 93 Until further evidence is available, estrogens should not be prescribed for the purpose of preventing or treating dementia.
Antiinflammatory drugs
There is strong epidemiologic evidence for a reduction of risk 94, 95 but negative results in mild-to-moderate AD. [96] [97] [98] [99] Currently, thre is no indication in AD (ongoing prevention study). 89, 100 Statins There is epidemiologic evidence for a reduction of risk. [101] [102] [103] [104] Studies are under way in MCI and mild AD.
Omega-3 fatty acid A growing body of evidence from biological, observational, and epidemiologic studies suggests a protective effect against dementia. No trial exists on the prevention of AD. 105 A recent trial in mild-to-moderate AD patients showed no statistically significant difference in cognition at 6 months and 1 year. However, in a small subgroup (n = 32) of very mild AD patients (MMSE > 27), there was arrested decline in MMSE scores at 6 months and 1 year, compared with placebo. A similar effect was observed when the placebo patients were switched to omega-3 fatty acid. 106 Omega-3 fatty acids may lower the rate of decline in very early AD patients and may play a role in primary prevention. Larger cohort studies are required.
Results of 2 clinical trials are expected in 2008. 105 ADCS-ADL sev, and SIB. There was also a significant effect on the NPI, which is discussed in the companion article. 3 Memantine has also been studied for efficacy in mild-to-moderate AD. An RCT (n = 403) 58 comparing memantine with placebo showed significant differences in the primary outcome measures of the ADAS-cog and the CIBIC+. There were differences in function on the ADCS-ADL at the end of 6 months. Other studies failed to show conclusive evidence of benefit at this stage of AD. On the basis of this information, there is at present no evidence to recommend the routine use of memantine in cases of mild AD.
Ginkgo Biloba
The use of Ginkgo biloba in AD is popular, although studies on its efficacy have had inconsistent results thus far. 62 ) was that Ginkgo biloba was safe and appeared to stabilize and improve the cognitive and social functioning of individuals with dementia for 6 months to 1 year. A later trial 17 involving patients with dementia (n = 36) and age-associated memory impairment (n = 87) compared Ginkgo biloba with placebo and showed no treatment benefit at the end of 6 months. A recent trial (n = 76) 63 published in 2006 randomized patients to Ginkgo biloba, donepezil 5 mg, or placebo. After 6 months, the Ginkgo biloba-treated group had comparable improvement in attention, memory, cognitive performance, and CGI score, compared with the donepezil-treated group.
Disease-Modifying Treatments
The main DMDs being tested currently target amyloid deposition. Antiamyloid therapeutic approaches are listed in Table 3 and discussed in this section. Other selected potential DMDs or strategies are listed in Table 4 .
Immunotherapy. The development of active or passive immunization against Ab is still very much in developmental stages. Unfortunately, the first human trial 64 on immunotherapy was halted owing to the development of meningoencephalitis in 18 patients (6% of the treatment group). Analysis of magnetic resonance imaging measurement of cerebral volume and ADAS-cog scores revealed accelerated loss of cerebral volume in the immunized group, with antibody response but stable cognitive scores. 65, 66 A case report on the autopsy of one patient who died after immunization did reveal almost complete removal of amyloid plaques from her brain. 67 Currently, a Phase II trial involving a monoclonal antibody (AAB-001) against Ab is in progress. 68 Other possible avenues of pursuit include immunoglobulins and immunization with shorter fragments of Ab, which may circumvent the complication of meningoencephalitis. 69, [70] [71] [72] [73] [74] Other Antiamyloid Therapies. The GAG mimetic 3-amino-1-propanesulfonic acid, also known as tramiprosate or Alzhemed, has demonstrated satisfactory safety and tolerability in mild-to-moderate AD 75 and is in Phase III of development. It is an orally administered, small organic molecule that binds to soluble Ab42 and is designed to interfere with the association between GAGs and Ab; thereby preventing GAGs from promoting b-sheet and amyloid formation. The resultant effect is twofold: prevention of the deposition of amyloid fibrils and inhibition of the inflammatory response associated with accumulation of Ab. The results of the North American pivotal study are pending.
MPC 7869 (R-flurbiprofen, or Flurizan) is an allosteric modulator of gammasecretase activity that is also in Phase III of development for treatment of mild-to-moderate AD. 76 It lowers Ab42 production by selectively modulating, but not inhibiting, gammasecretase activity to shift cleavage of amyloid precursor protein away from Ab42 production toward shorter, less toxic peptide fragments. Allosteric modulation would allow for gammasecretase to maintain activity for its other biological effects. The end result is lowered production of toxic amyloid (Ab42) and inhibition of the cascade of amyloid accumulation, plaque formation, and neurodegeneration. R-flurbiprofen, being the R-enantiomer of flurbiprofen (a nonsteroidal antiinflammatory drug), lacks significant cyclooxygenase-inhibiting activity and therefore has the added advantage of being well tolerated at high dosages, with reduced gastrointestinal and other side effects. Phase II trials have already shown Flurizan to be well tolerated over 24 months, with a reduced rate of decline and significant effects on cognition, ADL, and global function in patients with mild-to-moderate AD. A Phase III study is underway.
Other antiamyloid therapies in the form of beta-and gammasecretase inhibitors and alphasecretase promotors are still in developmental stages.
Issues in Pharmacotherapy Trial Designs and Outcomes
The remarkable developments in the treatment of AD over the past 2 decades confront us with new challenges and issues in regard to trial duration, design, methodology, and assessment of outcomes. Although earlier trials using crossover and parallel group designs with measured outcomes of cognition, such as the ADAS-cog, and global measures of change, such as the CIBIC+, have served us adequately in demonstrating the modest effects of ChEIs and memantine in the symptomatic treatment of AD, future trials will have to incorporate or consider the issues discussed below.
Measurement of More Clinically Meaningful Outcomes
Until surrogate markers of tracking the longitudinal course of AD (by blood, cerebrospinal fluid, brain imaging, or otherwise) are established, clinical assessments of cognition (such as the ADAS-cog) and function (such as the ADCS-ADL and Disability Assessment for Dementia 77 ), as well as global measures (such as the CIBIC+), will continue to be important in pivotal trials of new AD therapies. However, use of newer measures such as the GAS and SWE tool would be useful in measuring the impact of treatment on both the patient and caregivers. More studies on the impact of treatment on caregiver burden and quality of life will better demonstrate the utility of these drugs to health policy planners and aid them in justifying subsidized drug costs and availability to patients.
Trial Design
Trials demonstrating the symptomatic effects of ChEIs have employed parallel-group and crossover designs. To demonstrate disease-modifying effect, newer trial designs such as the staggered-start design may be employed. 78 An alternative would be a long-term, parallel-group design that shows increasing drug-placebo divergence in measure outcomes. 78
Trial Duration
The pivotal AD trials have demonstrated efficacy for 6 to 12 months, according to the ADAS-cog and global measures such as the CIBIC+. Therapeutic agents targeting different stages of AD would require different (and, in general, longer) trial durations to demonstrate efficacy. For example, The GuidAge 18 and Ginkgo Evaluation of Memory 19 trials test Ginkgo biloba against placebo in healthy older populations with no or some memory complaints over 5 to 7 years, respectively, with incident dementia as primary outcome. Populations with amnestic MCI can be tested with a symptomatic or a potential DMD, compared with placebo, over 3 years, with time to diagnosable dementia used as the primary outcome. 79 For studies on mild-to-moderate AD, patients must be offered the usual standard of care, to which a potential DMD (for example, tramiprostate or R-flurbiprofen) or placebo is added over 12 to 18 months, with slower decline on cognitive, global, or functional autonomy as the primary end points.
Patients with severe AD are usually in a nursing home setting and require shorter (for example, 6-month) studies with appropriate cognitive, functional, and behavioural outcomes. 39 Trials of longer duration are also important in demonstrating the impact of treatment on long-term disease milestones such as nursing-home placement and other features of disease progression. Other factors to consider in longer trials include dropout, medication compliance, and change in caregivers' perceptions of the patient's and their own needs.
Alternative Models of Statistical Analysis
In earlier trials of symptomatic treatment, the primary analysis focused on outcomes at end point, with LOCF or ITT used to compensate for missing values in the case of dropouts. Although LOCF or ITT have been favoured by the FDA, investigators and other regulatory agencies are now suggesting that, for studies of longer duration (that is, 12 months or more), the primary analysis should be based on observed cases (that is, on completers) to prevent treatment bias arising from LOCF or ITT analysis. For practical purposes, both types of analysis are performed in most trials. Emphasis on completers would require greater scrutiny of dropout rates (for example, dropout due to drug intolerance). Alternative models of analysis, including mixed-effects models, regression techniques, or assigning an average or worst-case outcome scenario to dropouts are being considered. 59 Other issues that need to be considered include the use of multiple comparisons and the correction of level of significance. 59 Responder analysis is becoming a very important component of planned analysis in clinical trials for AD. The ability to determine which drug class or drug within a class will help individual patients, according to their genotype and (or) disease phenotype, their age of onset, or the severity of their symptoms at time of treatment initiation, will become part of the long-term management of AD.
Use of Placebo and Add-On Therapy
ChEIs and memantine are now considered the standard treatment for AD. Hence, trials involving new agents will need to use add-on therapy designs comparing the new drug with placebo in AD patients who have been on stable dosages of standard treatment for at least 6 months. Head-to-head studies with the aim of demonstrating superiority, equivalence, or noninferiority-already widely used in trials involving new antihypertensive and antidepressant agents-may also become more prevalent. The use of new agents compared with placebo for symptomatic treatment of drug-naive patients still has a role, albeit in trials of shorter duration (for example, 3 months), allowing patients to be switched to standard treatment if no treatment benefit is observed after the initial period.
Patients With Multiple Comorbidities
The limited generalizability of trial results has often been highlighted; AD patients in studies frequently have fewer comorbid conditions and neuropsychiatric symptoms than patients seen typically in clinical practice. More trials on geriatric patients with multiple comorbidities, who are representative of most patients in the community, would be welcome.
Pharmacoeconomic Outcomes
With ageing populations and projected burgeoning numbers of AD patients, many countries will struggle with the issue of increasing subsidies or reimbursement of medications and other aspects of therapy. Despite the weight of evidence in favour of the safety and efficacy of ChEIs and memantine in AD treatment, there are ongoing debates on the costs and benefits of treating elderly individuals suffering from dementia. In the United Kingdom, the AD2000 trial resulted in the decision to subsidize treatment only with ChEIs and only for patients with moderate-stage disease. [80] [81] [82] There is a clear need for more studies that measure the cost-effectiveness of treatment and consider quality-adjusted life years and other aspects of pharmacoeconomics.
Newer Models of Analysis of Neuropsychiatric Symptoms
Although it is very significant clinically, the most difficult domain to study has been behaviour. Neuropsychiatric scales such as the NPI and the Behavioral Pathology in Alzheimer's Disease rating scale, 83 as well as specific scales such as Cohen-Mansfield Agitation Inventory, 84, 85 have not yet allowed unequivocal demonstration of benefit in the severe stages of AD. New methods to analyze behaviour have been proposed 86 and will likely be more successful in defining those categories of neuropsychiatric symptoms most responsive to ChEIs (for example, anxiety and hallucinations) and memantine (for example, agitation). This is discussed further in the companion article. 3
Conclusions
There is clear benefit from symptomatic treatment using ChEIs and memantine; in the coming years, however, significant advances in new therapeutic agents will enable us to offer more comprehensive and individualized pharmacotherapy at all stages of AD. This, together with continued development of nonpharmacologic therapies, will bring us closer to more complete treatment of AD.
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